DHARAM KUMBHANI, Section Chief, Interventional Cardiology
Dharam Kumbhani, M.D., is the Section Chief/Director of Interventional Cardiology and an Associate Professor of Medicine in UT Southwestern Medical Center’s Department of Internal Medicine. He is also the Director of the Cardiac Catheterization Laboratory at Clements University Hospital. He specializes in interventional cardiology.
Dr. Kumbhani earned his medical degree with honors at the University of Mumbai. He earned a master’s degree in clinical epidemiology at Harvard University before completing an internship and residency in internal medicine at the Hospital of the University of Pennsylvania and cardiovascular training at the Cleveland Clinic. He then completed fellowships in interventional cardiology and advanced structural and endovascular interventions and a postdoctoral research fellowship at Brigham and Women’s Hospital and Harvard Medical School, where he was also an instructor in cardiology.
He brings a strong background in advanced interventional cardiology techniques to UT Southwestern. His clinical practice specializes in transradial coronary interventions, percutaneous valve technologies, peripheral vascular interventions, and other adult structural heart disease interventions.
Dr. Kumbhani is also internationally recognized in the field of outcomes-based and quality-of-care research. He has authored or co-authored more than 150 articles in medical journals such as the New England Journal of Medicine, Journal of the American Medical Association, Journal of the American College of Cardiology, and Circulation, among others. He has received numerous grants for his research, including from the American Heart Association. He is an elected member of the American College of Epidemiology, the Sigma Xi Research Society, and the U.K.’s Royal College of Physicians.
He is an Associate Editor of Circulation and serves on the Editorial board of Cardiosource for the American College of Cardiology. He served as Co-Chair for the 2017 Expert Consensus Document on Transcatheter Aortic Valve Replacement.
No financial relationships have been disclosed.